Juno Therapeutics Inc. (JUNO)

86.96
0.09 0.10
Prev Close 86.87
Open 86.97
Day Low/High 86.90 / 87.01
52 Wk Low/High 19.62 / 87.01
Volume 3.70M
Avg Volume 4.51M
Exchange
Shares Outstanding 116.11M
Market Cap 10.10B
EPS -4.10
Div & Yield N.A. (N.A)
Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data

Juno, Kite, Novartis Yelp 'Oh Merde!' at Cellectis Off-the-Shelf CAR-T Data

Can Cellectis transform CAR-T from a cool cancer science experiment into a profitable business?

Juno Therapeutics To Report Third Quarter 2015 Financial Results On Tuesday, November 10

Juno Therapeutics To Report Third Quarter 2015 Financial Results On Tuesday, November 10

Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the third quarter of 2015 on Tuesday, November 10, 2015, after the close of U.

Before the Move: Watch Cellectis Into UCART19 Data

Before the Move: Watch Cellectis Into UCART19 Data

Gene engineering company Cellectis may present potentially crucial data on its UCART19 immuno-oncology treatment at the upcoming American Society of Hematology meeting.

Juno Therapeutics Appoints Robert Azelby As Chief Commercial Officer

Juno Therapeutics Appoints Robert Azelby As Chief Commercial Officer

Juno Therapeutics (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced the appointment of Robert Azelby as Executive Vice President,...

Northwest Bio Bothers British Bestie for Bounteous Bucks

Northwest Bio Bothers British Bestie for Bounteous Bucks

British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.

Patience Is a Virtue in This Dull Market

A rally that's still to come is where we could see a real change in sentiment, not the minor ones we’re witnessing now.

Juno Therapeutics (JUNO) Stock Could Lead the Way to a Biotech Bounce

Juno Therapeutics (JUNO) Stock Could Lead the Way to a Biotech Bounce

We're watching the SPDR S&P Biotech ETF and its components for clues to a rally. Rejected lows in the charts have been encouraging.

Charting a Biotech Bounce

We're watching the SPDR S&P Biotech ETF for clues to a rally. Rejected lows in the charts have been encouraging.

4 Outperforming Momentum Stocks to Watch

4 Outperforming Momentum Stocks to Watch

Here are four stocks to watch with exceptional relative strength and technical momentum.

4 Stocks Breaking Out on Big Volume

4 Stocks Breaking Out on Big Volume

These stocks rising on unusual volume are within range of triggering breakout trades.

Juno Therapeutics To Present At The 2015 Leerink Partners Immuno-Oncology Roundtable

Juno Therapeutics To Present At The 2015 Leerink Partners Immuno-Oncology Roundtable

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 2015 Leerink Partners Immuno-Oncology Roundtable at 8:25 a.

Juno Therapeutics To Present At The 2015 Morgan Stanley Global Healthcare Conference

Juno Therapeutics To Present At The 2015 Morgan Stanley Global Healthcare Conference

Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 2015 Morgan Stanley Global Healthcare Conference at 4:15 p.

Biotechs Get Crash Course on Corrections

They're following similar pattern to gold and Chinese stocks.

The Numbers Behind Biotech's Horrible, No Good, Awful August

The Numbers Behind Biotech's Horrible, No Good, Awful August

Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.

Biotech Selloff Has No Effect on Cellectis Advances: CEO

Biotech Selloff Has No Effect on Cellectis Advances: CEO

The selloff in immunotherapy stocks is purely market-based and does not reflect the stunning advances in the cancer fighting space, said Dr. Andre Choulika, CEO of Cellectis S.A.

Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO

Biotech Selloff Does Not Dim Immunotherapy Advances Says Cellectis CEO

The selloff in immunotherapy stocks is purely market-based and does not reflect the stunning advances in the cancer fighting space, said Dr. Andre Choulika, CEO of Cellectis S.A.

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

Biotech columnist Adam Feuerstein answers readers' questions about health care.

'Mad Money' Lightning Round: Monster Beverage Is the One to Buy

'Mad Money' Lightning Round: Monster Beverage Is the One to Buy

Cramer is bullish on Voya Financial, Cheniere Energy and Box.

Jim Cramer's 'Mad Money' Recap: This Stock Market Is No Bargain

Jim Cramer's 'Mad Money' Recap: This Stock Market Is No Bargain

With over 60 stocks in the Dow Jones Industrial Average making new lows and entire sectors faltering, buying on the dip may be a thing of the past.

4 Momentum Charts to Watch

4 Momentum Charts to Watch

A lot of stocks we follow are continuing their upward moves after a brief market swoon.

Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie

Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie

Biotech columnist Adam Feuerstein answers readers' questions about health care.

'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch

'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch

The trading panel discusses what to buy and what to avoid.

A Trend and a Counter-Trend Trade

A Trend and a Counter-Trend Trade

I used to be against buying the counter-trend, but not anymore.

Blame the E.U.; Don't Ignore the Good News; ... But Stay Skeptical: Jim Cramer's Best Blogs

Blame the E.U.; Don't Ignore the Good News; ... But Stay Skeptical: Jim Cramer's Best Blogs

Catch up on Jim Cramer's ideas from this past week as he discusses how the E.U. abetted the Greek crisis, good news we're ignoring, and whether it's time to bargain-hunt.

Market News: Apollo Education Group, Epizyme, Juno Therapeutics

Market News: Apollo Education Group, Epizyme, Juno Therapeutics

The stock markets in the United States rallied today after suffering a significant decline yesterday due to investors' concerns regarding the potential exit of Greece in the Eurozone. Sign up for o...

Market Wrap: Quarter Ends on Positive Note

Stocks churn over headlines on Greece.